Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients

References

• Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med. 2010;28:204–217. doi:10.1055/s-0030-125147720414843
   PubMed Web of Science ®Google Scholar
• Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206:e211–e219. doi:10.1016/j.ajog.2011.12.002
   PubMed Web of Science ®Google Scholar
• Styer AK, Rueda BR. The epidemiology and genetics of uterine leiomyoma. Best Pract Res Clin Obstet Gynaecol. 2016;34:3–12. doi:10.1016/j.bpobgyn.2015.11.01826725703
   PubMed Web of Science ®Google Scholar
• Reichardt P. The treatment of uterine sarcomas. Ann Oncol. 2012;23(Suppl 10):x151–x157. doi:10.1093/annonc/mds35922987952
   PubMedGoogle Scholar
• Reiter RC, Wagner PL, Gambone JC. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol. 1992;79:481–484.1553162
   PubMed Web of Science ®Google Scholar
• Paul PG, Rengaraj V, Das T, Garg R, Thomas M, Khurd AS. Uterine sarcomas in patients undergoing surgery for presumed leiomyomas: 10 years’ experience. J Minim Invasive Gynecol. 2016;23:384–389. doi:10.1016/j.jmig.2015.11.01226677821
   PubMed Web of Science ®Google Scholar
• Zhao WC, Bi FF, Li D, Yang Q. Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases. Onco Targets Ther. 2015;8:2943–2948.26508879
   PubMed Web of Science ®Google Scholar
• Tan-Kim J, Hartzell KA, Reinsch CS, et al. Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation. Am J Obstet Gynecol. 2015;212:594.e1–594.e10. doi:10.1016/j.ajog.2014.12.002
   PubMed Web of Science ®Google Scholar
• Rovirosa A, Ascaso C, Ordi J, et al. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys. 2002;52:1320–1329. doi:10.1016/S0360-3016(01)02808-511955745
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 2011;121(2):328–333. doi:10.1016/j.ygyno.2011.01.02221316747
   PubMed Web of Science ®Google Scholar
• Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–364. doi:10.1111/j.1365-2559.2009.03231.x19236512
   PubMed Web of Science ®Google Scholar
• Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145:61–70. doi:10.1016/j.ygyno.2017.02.01228317559
   PubMed Web of Science ®Google Scholar
• Buscema J, McLellan R. Uterine sarcomas In: Bieber EJ, Sanfilippo JS, Horowitz IR, Shafi MI, editors. Clinical Gynecology. Cambridge: Cambridge University Press; 2015:769–778.
   Google Scholar
• D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–139. doi:10.1016/j.ygyno.2009.09.02319853898
   PubMed Web of Science ®Google Scholar
• Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18:68. doi:10.1007/s11912-016-0552-727718181
   PubMed Web of Science ®Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104:177–178. doi:10.1016/j.ijgo.2008.12.00819135669
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137:581–588. doi:10.1016/j.ygyno.2015.03.04125805398
   PubMed Web of Science ®Google Scholar
• Zhang J, Li T, Zhang J, Zhu L, Lang J, Leng J. Clinical characteristics and prognosis of unexpected uterine sarcoma after hysterectomy for presumed myoma with and without transvaginal scalpel morcellation. Int J Gynecol Cancer. 2016;26:456–463. doi:10.1097/IGC.000000000000063826807642
   PubMed Web of Science ®Google Scholar
• Gao Y, Meng H, Zhang Y, Jiao T, Hui N. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. Int J Clin Exp Pathol. 2014;7:1616–1624.24817958
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HS, Nam EJ, Kim SW, Kim S, Kim YT. Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. BMC Cancer. 2016;16:675. doi:10.1186/s12885-016-2727-x27553655
   PubMed Web of Science ®Google Scholar
• Cusidó M, Fargas F, Baulies S, et al. Impact of surgery on the evolution of uterine sarcomas. J Minim Invasive Gynecol. 2015;22:1068–1074. doi:10.1016/j.jmig.2015.05.02426070730
   PubMed Web of Science ®Google Scholar
• Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014;132:360–365. doi:10.1016/j.ygyno.2013.11.02424296345
   PubMed Web of Science ®Google Scholar
• Park JY, Park SK, Kim DY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122:255–259. doi:10.1016/j.ygyno.2011.04.02121565389
   PubMed Web of Science ®Google Scholar
• Lin LL, Brown JC, Segal S, Schmitz KH. Quality of life, body mass index, and physical activity among uterine cancer patients. Int J Gynecol Cancer. 2014;24:1027–1032. doi:10.1097/IGC.000000000000016624927246
   PubMed Web of Science ®Google Scholar
• Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589–1592. doi:10.1126/science.111206315947177
   PubMed Web of Science ®Google Scholar
• Ethun CG, Postlewait LM, Le N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US extrahepatic biliary malignancy consortium. JAMA Surg. 2017;152:143–149. doi:10.1001/jamasurg.2016.364227784058
   PubMed Web of Science ®Google Scholar
• FDA. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids: summary and key findings 2014. Available from: http://www.fda.gov/downloads/MedicalDevices/Safety/AlertsandNotices/UCM393589.pdf. Accessed 1130, 2016.
   Google Scholar
• Damasco MR, Chan PK, Slonim M, Ang WC, Healey MG. Incidence of malignancy and myoma variants at surgery for presumed benign symptomatic myomas. J Minim Invasive Gynecol. 2017;24:659–664. doi:10.1016/j.jmig.2017.02.01228216458
   PubMed Web of Science ®Google Scholar
• Lieng M, Berner E, Busund B. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. J Minim Invasive Gynecol. 2015;22:410–414. doi:10.1016/j.jmig.2014.10.02225460521
   PubMedGoogle Scholar
• Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol. 2015;125:397–405. doi:10.1097/AOG.000000000000064225569001
   PubMed Web of Science ®Google Scholar
• Kho KA, Lin K, Hechanova M, Richardson DL. Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Obstet Gynecol. 2016;127:468–473. doi:10.1097/AOG.000000000000124226855091
   PubMed Web of Science ®Google Scholar
• Raine-Bennett T, Tucker LY, Zaritsky E, et al. Occult uterine sarcoma and leiomyosarcoma incidence of and survival associated with morcellation. Obstet Gynecol. 2016;127:29–39. doi:10.1097/AOG.000000000000118726646120
   PubMed Web of Science ®Google Scholar
• Ruengkhachorn I, Phithakwatchara N, Nawapun K, Hanamornroongruang S. Undiagnosed uterine sarcomas identified during surgery for presumed leiomyoma at a national tertiary hospital in Thailand: a 10-year review. Int J Gynecol Cancer. 2017;27:973–978. doi:10.1097/IGC.000000000000096828498251
   PubMed Web of Science ®Google Scholar
• Pavlakis K, Messini I, Yiannou P, et al. Morcellating uterine mesenchymal tumors: the pathologist’s view. J Obstet Gynaecol Res. 2017;43:580–586. doi:10.1111/jog.1320128120430
   PubMed Web of Science ®Google Scholar
• Yang H, Li XC, Yao C, et al. Proportion of uterine malignant tumors in patients with laparoscopic myomectomy: a national multicenter study in China. Chin Med J. 2017;130:2661–2665. doi:10.4103/0366-6999.21800829133752
   PubMed Web of Science ®Google Scholar